Prescription medicine
Brinzolamide Brand names: Azopt
Brinzolamide (Azopt) is a prescription medicine with an FDA approval on record since 1998. FDA's NDC Directory lists it from 4 generic labelers, and pharmacies paid $9.00 per mL (Brinzolamide 1% eye drops) in the October 7, 2026 NADAC survey.
- Generic listed
Check it at the source: the brinzolamide FDA label on DailyMed (effective November 24, 2023, Sandoz Inc); the NDA 20816 record on Drugs@FDA; every brinzolamide label on DailyMed.
Highlights of the record
FDA label of November 24, 2023; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageAZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
Forms and strengths
- 10 mg/ml
Suspension/ drops.
On the market
- Earliest approval on file
- April 1, 1998 Azopt, Sandoz; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 3 first November 27, 2020; 2 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 5 of which 4 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $9.00 per mL Brinzolamide 1% eye drops
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- 1 since 2021 0 Class I among all firms' recalls; latest December 8, 2021
- FAERS reports
- 8,636 through July 30, 2026
What is brinzolamide used for?
From the label: indications and usageAZOPT is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. AZOPT is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.
Conditions named in the indications of brinzolamide's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Carbonic Anhydrase Inhibitor.
Source: FDA drug label (Azopt), Sandoz Inc, effective November 24, 2023 (SPL set 0afb6589-51ba-432c-aed1-20a12d5d3455), via openFDA; the full label on DailyMed
Is there a generic for brinzolamide (Azopt)?
The FDA approved the first generic brinzolamide on November 27, 2020. 3 generic applications are approved; 2 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists brinzolamide from 4 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1998 earliest approval on file
- 2020 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for brinzolamide (Azopt)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $9.00 per mL (Brinzolamide 1% eye drops), down 22% from $11.47 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Brinzolamide 1% eye drops (generic)
- Azopt 1% eye drops (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Brinzolamide 1% eye drops | Generic | $9.00 per mL | n/a | -22% |
| Azopt 1% eye drops | Brand | $35.18 per mL | n/a | -0.1% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Has brinzolamide been recalled?
The FDA's Enforcement Report lists 1 recall naming brinzolamide since 2021: 0 Class I (the most serious), 1 Class II, 0 Class III; 0 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 8, 2021 | Class II | Teva Pharmaceuticals USA | Defective Container: The notch in the cap that fits into the nozzle of the dropper could break off and block the dropper possibly resulting in the product not … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the brinzolamide label say about other medicines?
The brinzolamide label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Benzalkonium | warnings and precautions | The preservative in AZOPT, benzalkonium chloride, may be absorbed by soft contact lenses. |
Source: FDA drug label (Azopt), Sandoz Inc, effective November 24, 2023 (SPL set 0afb6589-51ba-432c-aed1-20a12d5d3455), via openFDA; the full label on DailyMed
What do FAERS reports show for brinzolamide?
The FDA Adverse Event Reporting System holds 8,636 reports that list brinzolamide among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 638 are coded as a death and 1,914 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2020 (1,947, against a median of 490 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as brinzolamide?
16 other medicines are given the same way (ophthalmic) and in the same FDA class as brinzolamide or labeled mainly for the same use (glaucoma), the same class first. Glaucoma lists all 20 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (ophthalmic) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Dorzolamide and timolol | Glaucoma | 14 labelers | $0.893 per mL Dorzolamide-timolol eye drops | No current entry |
| Dorzolamide | Glaucoma | 14 labelers | $0.835 per mL 2% eye drops | No current entry |
| Timolol | Glaucoma | 21 labelers | $0.774 per mL 0.5% eye drops | No current entry |
| Brimonidine | Glaucoma | 12 labelers | $9.06 per mL 0.1% drop | No current entry |
| Bimatoprost | Glaucoma | 13 labelers | $6.97 per mL 0.03% eye drops | No current entry |
| Brimonidine and timolol | Glaucoma | 14 labelers | $2.15 per mL 0.2%-0.5% | No current entry |
| Latanoprost | Glaucoma | 14 labelers | $1.58 per mL 0.005% eye drops | No current entry |
| Travoprost | Glaucoma | 11 labelers | $9.07 per mL 0.004% eye drop | A presentation being discontinued |
Every medicine labeled for the same conditions as brinzolamide
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to brinzolamide
- 16 medicines for the same use
- Other carbonic anhydrase inhibitors
- the pharmacologic class, with prices and generics
- Brinzolamide side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other